Hansa Biopharma: Improved use of IDEFIRIX - Redeye

Hansa delivers a healthy increase in patients using IDEFIRIX. The impact on the valuation and the outlook is now related to the outlook for discounts and rebates, which are set to stabilize at a lower level going forward. In Q3, the total level of these provisions was approximately 43%. When adjusting for provisions actually relating to Q3, net sales would have been a very impressive SEK 64.6m and rebates of 7%. Our Base Case is SEK 125 (120) with an unchanged Bull Case of SEK 220 and a Bear Case of SEK 15.

Länk till analysen i sin helhet: https://www.redeye.se/research/1044186/hansa-biopharma-improved-use-of-idefirix?utm_source=finwire&utm_medium=RSS